- Home
- KMB vs IQV Comparison
KMB vs IQV Comparison
Compare KMB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMB
- IQV
- Stock Information
- Founded
- KMB 1910
- IQV 1982
- Country
- KMB United States
- IQV United States
- Employees
- KMB N/A
- IQV N/A
- Industry
- KMB Containers/Packaging
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- KMB Consumer Discretionary
- IQV Health Care
- Exchange
- KMB Nasdaq
- IQV Nasdaq
- Market Cap
- KMB 48.7B
- IQV 41.8B
- IPO Year
- KMB N/A
- IQV 2013
- Fundamental
- Price
- KMB $146.94
- IQV $243.24
- Analyst Decision
- KMB Hold
- IQV Buy
- Analyst Count
- KMB 16
- IQV 17
- Target Price
- KMB $144.88
- IQV $266.25
- AVG Volume (30 Days)
- KMB 1.6M
- IQV 766.4K
- Earning Date
- KMB 10-22-2024
- IQV 10-30-2024
- Dividend Yield
- KMB 3.30%
- IQV N/A
- EPS Growth
- KMB 39.38
- IQV 32.55
- EPS
- KMB 6.76
- IQV 7.71
- Revenue
- KMB $20,280,000,000.00
- IQV $15,155,000,000.00
- Revenue This Year
- KMB $0.21
- IQV $4.29
- Revenue Next Year
- KMB $0.79
- IQV $6.67
- P/E Ratio
- KMB $21.73
- IQV $31.60
- Revenue Growth
- KMB N/A
- IQV 3.23
- 52 Week Low
- KMB $116.32
- IQV $167.42
- 52 Week High
- KMB $149.31
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- KMB 62.08
- IQV 50.54
- Support Level
- KMB $142.68
- IQV $246.85
- Resistance Level
- KMB $149.31
- IQV $252.69
- Average True Range (ATR)
- KMB 1.63
- IQV 4.62
- MACD
- KMB 0.38
- IQV -0.69
- Stochastic Oscillator
- KMB 64.63
- IQV 32.26
About KMB Kimberly-Clark Corporation
With more than half of sales from personal care and another third from consumer tissue products, Kimberly-Clark sits as a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.